Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Wild Ride For Immunology? New Mechanisms, Big Indications Up For US FDA Approval In 2022

Executive Summary

Major R&D efforts in immuno-dermatology produced multiple novel candidates in atopic dermatitis and psoriasis, while alopecia areata and vitiligo might see first therapies and JAK safety and COVID-19 logjams resolve.

You may also be interested in...



Keeping Track: Marinus’ Ztalmy Continues US FDA’s Orphan Streak; AZ Gets Adjuvant Nod For Lynparza, Fasenra CRL

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

AbbVie Says Rinvoq Holding Up, Humira Erosion Will Continue Into 2024

Physician response to FDA’s label change limiting Rinvoq to second-line-plus has been as expected, AbbVie said. Humira passed the $20bn sales threshold in 2021, but US biosimilar competition is one year away.

Lilly Says Safety Not A Factor In Dropping Lupus Development With Olumiant

The pharma also warns that an FDA complete response letter could be coming for its supplemental NDA to add atopic dermatitis to the JAK1 inhibitor’s label.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS145663

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel